Top

Published in:

01-01-2019 | Nephrology - Review

Vitamin D and calcium kidney stones: a review and a proposal

Authors: Sanaz Tavasoli, Maryam Taheri

Published in: International Urology and Nephrology | Issue 1/2019

Abstract

Urolithiasis is a common, highly recurrent disease with increasing prevalence worldwide. The association between vitamin D and calcium stones has often been investigated on the basis of the role of vitamin D in calcium homeostasis. Currently, there is no consensus on the management of vitamin D deficiency in patients with renal calculi, because of controversies about the relationship between vitamin D and calcium stones. However, the vitamin D deficiency is shown to be highly prevalent among kidney stone formers, and some studies found a higher prevalence in stone formers compared with non-stone formers. This article attempts to review the relationship between calcium stones and vitamin D, and propose a mechanism for the association between vitamin D deficiency and calcium-based calculi according to the substantial role of inflammation and oxidative stress in calcium stone formation and also the pro-inflammatory effect of vitamin D deficiency.

Alelign T, Petros B (2018) Kidney stone disease: an update on current concepts. Adv Urol https://doi.org/10.1155/2018/3068365 CrossRefPubMedPubMedCentral

Knoll T (2010) Epidemiology, pathogenesis, and pathophysiology of urolithiasis. Eur Urol Suppl 9(12):802–806. https://doi.org/10.1016/j.eursup.2010.11.006 CrossRef

Hosseini MM, Shakeri S, Manaheji F, Aminsharifi A, Ezatzadegan S, Pakfetrat M, Basiratnia M, Hosseini M (2014) Stone composition in patients who undergo renal stone surgery: review of 423 stone analyses in southern Iran. Iran J Med Sci 39(1):75–76PubMedPubMedCentral

Tiselius HG (2011) A hypothesis of calcium stone formation: an interpretation of stone research during the past decades. Urol Res 39(4):231–243. https://doi.org/10.1007/s00240-010-0349-3 CrossRefPubMed

West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H (2008) Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988–1994. Am J Kidney Dis 51(5):741–747. https://doi.org/10.1053/j.ajkd.2007.12.030 CrossRefPubMed

Kohjimoto Y, Sasaki Y, Iguchi M, Matsumura N, Inagaki T, Hara I (2013) Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis 61(6):923–929. https://doi.org/10.1053/j.ajkd.2012.12.028 CrossRefPubMed

Polat EC, Ozcan L, Cakir SS, Dursun M, Otunctemur A, Ozbek E (2015) Relationship between calcium stone disease and metabolic syndrome. Urol J 12(6):2391–2395PubMed

Lieske JC (2014) New insights regarding the interrelationship of obesity, diet, physical activity, and kidney stones. J Am Soc Nephrol 25(2):211–212. https://doi.org/10.1681/asn.2013111189 CrossRefPubMed

Khan SR (2012) Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res 40(2):95–112. https://doi.org/10.1007/s00240-011-0448-9 CrossRefPubMedPubMedCentral

10.

Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, El-Hajj Fuleihan G, Josse RG, Lips P, Morales-Torres J, Group IOFCoSANW (2009) Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 20(11):1807–1820. https://doi.org/10.1007/s00198-009-0954-6 CrossRefPubMed

11.

Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22(4):477–501. https://doi.org/10.1210/edrv.22.4.0437 CrossRefPubMed

12.

Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266–281. https://doi.org/10.1056/NEJMra070553 CrossRefPubMed

13.

Kendrick J, Targher G, Smits G, Chonchol M (2009) 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 205(1):255–260. https://doi.org/10.1016/j.atherosclerosis.2008.10.033 CrossRefPubMed

14.

Carbone F, Mach F, Vuilleumier N, Montecucco F (2014) Potential pathophysiological role for the vitamin D deficiency in essential hypertension. World J Cardiol 6(5):260–276. https://doi.org/10.4330/wjc.v6.i5.260 CrossRefPubMedPubMedCentral

15.

Prasad P, Kochhar A (2016) Interplay of vitamin D and metabolic syndrome: a review. Diabetes Metab Syndr 10:105–112. https://doi.org/10.1016/j.dsx.2015.02.014 CrossRefPubMed

16.

Chiu KC, Chu A, Go VL, Saad MF (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79(5):820–825CrossRefPubMed

17.

Moukayed M, Grant WB (2013) Molecular link between vitamin D and cancer prevention. Nutrients 5(10):3993–4021. https://doi.org/10.3390/nu5103993 CrossRefPubMedPubMedCentral

18.

IOM (Institute of Medicine) (2011) Dietary reference Intakes for calcium and vitamin D. National Academies Press, US, Washington, D. C. https://doi.org/10.17226/13050 CrossRef

19.

Carlberg C (2014) The physiology of vitamin D-far more than calcium and bone. Front Physiol 5:335. https://doi.org/10.3389/fphys.2014.00335 CrossRefPubMedPubMedCentral

20.

Sharifi N, Amani R, Hajiani E, Cheraghian B (2014) Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? a randomized clinical trial. Endocrine 47(1):70–80. https://doi.org/10.1007/s12020-014-0336-5 CrossRefPubMed

21.

Tang J, Chonchol MB (2013) Vitamin D and kidney stone disease. Curr Opin Nephrol Hypertens 22(4):383–389. https://doi.org/10.1097/MNH.0b013e328360bbcd CrossRefPubMed

22.

Elkoushy MA, Sabbagh R, Unikowsky B, Andonian S (2012) Prevalence and metabolic abnormalities of vitamin D-inadequate patients presenting with urolithiasis to a tertiary stone clinic. Urology 79(4):781–785. https://doi.org/10.1016/j.urology.2011.09.004 CrossRefPubMed

23.

Johri N, Jaeger P, Ferraro PM, Shavit L, Nair D, Robertson WG, Gambaro G, Unwin RJ (2017) Vitamin D deficiency is prevalent among idiopathic stone formers, but does correction pose any risk? Urolithiasis 45:535–543CrossRefPubMed

24.

Ticinesi A, Nouvenne A, Ferraro PM, Folesani G, Lauretani F, Allegri F, Guerra A, Cerundolo N, Aloe R, Lippi G, Maggio M, Gambaro G, Borghi L, Meschi T (2016) Idiopathic calcium nephrolithiasis and hypovitaminosis D: a case-control study. Urology 87:40–45. https://doi.org/10.1016/j.urology.2015.10.009 CrossRefPubMed

25.

Giron-Prieto MS, Del Carmen Cano-Garcia M, Arrabal-Polo MA, Poyatos-Andujar A, Quesada-Charneco M, de Haro-Munoz T, Arias-Santiago S, Arrabal-Martin M (2016) Analysis of vitamin D deficiency in calcium stone-forming patients. Int Urol Nephrol. https://doi.org/10.1007/s11255-016-1290-3 CrossRefPubMed

26.

Vestergaard P (2015) Primary hyperparathyroidism and nephrolithiasis. Ann Endocrinol (Paris) 76(2):116–119. https://doi.org/10.1016/j.ando.2015.03.002 CrossRef

27.

Sayer JA, Carr G, Simmons NL (2004) Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. Clin Sci (Lond) 106(6):549–561. https://doi.org/10.1042/cs20040048 CrossRef

28.

Shavit L, Jaeger P, Unwin RJ (2015) What is nephrocalcinosis? Kidney Int 88(1):35–43. https://doi.org/10.1038/ki.2015.76 CrossRefPubMed

29.

Oliveira B, Kleta R, Bockenhauer D, Walsh SB (2016) Genetic, pathophysiological, and clinical aspects of nephrocalcinosis. Am J Physiol Renal Physiol 311(6):F1243–Ff1252. https://doi.org/10.1152/ajprenal.00211.2016 CrossRefPubMed

30.

Bhojani N, Paonessa JE, Hameed TA, Worcester EM, Evan AP, Coe FL, Borofsky MS, Lingeman JE (2015) Nephrocalcinosis in calcium stone formers who do not have systemic disease. J Urol 194(5):1308–1312. https://doi.org/10.1016/j.juro.2015.05.074 CrossRefPubMedPubMedCentral

31.

Daudon M, Letavernier E, Frochot V, Haymann JP, Bazin D, Jungers P (2016) Respective influence of calcium and oxalate urine concentration on the formation of calcium oxalate monohydrate or dihydrate crystals. C R Chim 19(11–12):1504–1513. https://doi.org/10.1016/j.crci.2016.08.009 CrossRef

32.

Tsujihata M (2008) Mechanism of calcium oxalate renal stone formation and renal tubular cell injury. Int J Urol 15(2):115–120. https://doi.org/10.1111/j.1442-2042.2007.01953.x CrossRefPubMed

33.

Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 38(3):147–160. https://doi.org/10.1007/s00240-010-0271-8 CrossRefPubMedPubMedCentral

34.

Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, Traxer O, Tiselius HG (2016) Kidney stones. Nat Rev Dis Primers 2:16008. https://doi.org/10.1038/nrdp.2016.8 CrossRefPubMedPubMedCentral

35.

Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46(3):847–854CrossRefPubMed

36.

Evan AP (2010) Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 25(5):831–841. https://doi.org/10.1007/s00467-009-1116-y CrossRefPubMed

37.

Evan AP, Worcester EM, Coe FL, Williams J Jr, Lingeman JE (2015) Mechanisms of human kidney stone formation. Urolithiasis 43(Suppl 1):19–32. https://doi.org/10.1007/s00240-014-0701-0 CrossRefPubMed

38.

Verkoelen CF (2006) Crystal retention in renal stone disease: a crucial role for the glycosaminoglycan hyaluronan? J Am Soc Nephrol 17(6):1673–1687. https://doi.org/10.1681/ASN.2006010088 CrossRefPubMed

39.

Sakhaee K (2009) Recent advances in the pathophysiology of nephrolithiasis. Kidney Int 75(6):585–595. https://doi.org/10.1038/ki.2008.626 CrossRefPubMed

40.

Wiessner JH, Hung LY, Mandel NS (2003) Crystal attachment to injured renal collecting duct cells: influence of urine proteins and pH. Kidney Int 63(4):1313–1320. https://doi.org/10.1046/j.1523-1755.2003.00866.x CrossRefPubMed

41.

Umekawa T, Iguchi M, Uemura H, Khan SR (2006) Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts. BJU Int 98(3):656–660. https://doi.org/10.1111/j.1464-410X.2006.06334.x CrossRefPubMed

42.

Asselman M, Verhulst A, De Broe ME, Verkoelen CF (2003) Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 14(12):3155–3166CrossRefPubMed

43.

Khan SR (2006) Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 34(2):86–91. https://doi.org/10.1007/s00240-005-0016-2 CrossRefPubMed

44.

Thamilselvan V, Menon M, Thamilselvan S (2009) Oxalate-induced activation of PKC-alpha and -delta regulates NADPH oxidase-mediated oxidative injury in renal tubular epithelial cells. Am J Physiol Renal Physiol 297(5):F1399–F1410. https://doi.org/10.1152/ajprenal.00051.2009 CrossRefPubMedPubMedCentral

45.

Thamilselvan V, Menon M, Thamilselvan S (2014) Oxalate at physiological urine concentrations induces oxidative injury in renal epithelial cells: effect of alpha-tocopherol and ascorbic acid. BJU Int. https://doi.org/10.1111/bju.12642 CrossRefPubMed

46.

Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M (2003) Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111(5):607–616. https://doi.org/10.1172/JCI200317038 CrossRefPubMedPubMedCentral

47.

Evan A, Lingeman J, Coe FL, Worcester E (2006) Randall’s plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 69(8):1313–1318. https://doi.org/10.1038/sj.ki.5000238 CrossRefPubMed

48.

Khan SR (2013) Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol 189(3):803–811. https://doi.org/10.1016/j.juro.2012.05.078 CrossRefPubMed

49.

Evan AP, Coe FL, Lingeman JE, Shao Y, Sommer AJ, Bledsoe SB, Anderson JC, Worcester EM (2007) Mechanism of formation of human calcium oxalate renal stones on Randall’s plaque. Anat Rec (Hoboken) 290(10):1315–1323. https://doi.org/10.1002/ar.20580 CrossRef

50.

Kuo RL, Lingeman JE, Evan AP, Paterson RF, Parks JH, Bledsoe SB, Munch LC, Coe FL (2003) Urine calcium and volume predict coverage of renal papilla by Randall’s plaque. Kidney Int 64(6):2150–2154. https://doi.org/10.1046/j.1523-1755.2003.00316.x CrossRefPubMed

51.

Taylor ER, Stoller ML (2015) Vascular theory of the formation of Randall plaques. Urolithiasis 43(Suppl 1):41–45. https://doi.org/10.1007/s00240-014-0718-4 CrossRefPubMed

52.

Khan SR, Rodriguez DE, Gower LB, Monga M (2012) Association of Randall plaque with collagen fibers and membrane vesicles. J Urol 187(3):1094–1100. https://doi.org/10.1016/j.juro.2011.10.125 CrossRefPubMedPubMedCentral

53.

Taguchi K, Hamamoto S, Okada A, Unno R, Kamisawa H, Naiki T, Ando R, Mizuno K, Kawai N, Tozawa K, Kohri K, Yasui T (2017) Genome-wide gene expression profiling of Randall’s plaques in calcium oxalate stone formers. J Am Soc Nephrol 28(1):333–347. https://doi.org/10.1681/asn.2015111271 CrossRefPubMed

54.

Joshi S, Peck AB, Khan SR (2013) NADPH oxidase as a therapeutic target for oxalate induced injury in kidneys. Oxid Med Cell Longev. https://doi.org/10.1155/2013/462361 CrossRefPubMedPubMedCentral

55.

Khan SR (2014) Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol 3(3):256–276. https://doi.org/10.3978/j.issn.2223-4683.2014.06.04 CrossRefPubMedPubMedCentral

56.

Tsuji H, Wang W, Sunil J, Shimizu N, Yoshimura K, Uemura H, Peck AB, Khan SR (2016) Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury. World J Urol 34(1):89–95. https://doi.org/10.1007/s00345-015-1563-y CrossRefPubMed

57.

Umekawa T, Hatanaka Y, Kurita T, Khan SR (2004) Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J Am Soc Nephrol 15(3):635–644CrossRefPubMed

58.

Chaturvedi LS, Koul S, Sekhon A, Bhandari A, Menon M, Koul HK (2002) Oxalate selectively activates p38 mitogen-activated protein kinase and c-Jun N-terminal kinase signal transduction pathways in renal epithelial cells. J Biol Chem 277(15):13321–13330. https://doi.org/10.1074/jbc.M108203200 CrossRefPubMed

59.

Han HJ, Lim MJ, Lee YJ (2004) Oxalate inhibits renal proximal tubule cell proliferation via oxidative stress, p38 MAPK/JNK, and cPLA2 signaling pathways. Am J Physiol Cell Physiol 287(4):C1058–C1066. https://doi.org/10.1152/ajpcell.00063.2004 CrossRefPubMed

60.

Tugcu V, Ozbek E, Kemahli E, Cekmen MB, Caner N, Somay A, Erturkuner P, Seckin I, Demir CG, Altug T, Tasci AI (2007) Rapid communication: protective effect of a nuclear factor kappaB inhibitor, pyrolidium dithiocarbamate, in the kidney of rats with nephrolithiasis induced by ethylene glycol. J Endourol 21(9):1097–1106. https://doi.org/10.1089/end.2007.0074 CrossRefPubMed

61.

Umekawa T, Tsuji H, Uemura H, Khan SR (2009) Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int 104(1):115–120. https://doi.org/10.1111/j.1464-410X.2009.08374.x CrossRefPubMedPubMedCentral

62.

Carrasco-Valiente J, Anglada-Curado FJ, Aguilar-Melero P, Gonzalez-Ojeda R, Muntane-Relat J, Padillo-Ruiz FJ, Requena-Tapia MJ (2012) State of acute phase markers and oxidative stress in patients with kidney stones in the urinary tract. Actas Urol Esp 36(5):296–301. https://doi.org/10.1016/j.acuro.2011.08.004 CrossRefPubMed

63.

Huang HS, Ma MC, Chen CF, Chen J (2003) Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 62(6):1123–1128CrossRefPubMed

64.

Kittikowit W, Waiwijit U, Boonla C, Ruangvejvorachai P, Pimratana C, Predanon C, Ratchanon S, Tosukhowong P (2014) Increased oxidative DNA damage seen in renal biopsies adjacent stones in patients with nephrolithiasis. Urolithiasis 42(5):387–394. https://doi.org/10.1007/s00240-014-0676-x CrossRefPubMed

65.

Liu Z, Wang T, Yang J, Wang S, Yang W, Liu J, Ye Z (2012) Calcium oxalate monohydrate crystals stimulate monocyte chemoattractant protein-1 and transforming growth factor beta1 expression in human renal epithelial cells. Mol Med Rep 5(5):1241–1244. https://doi.org/10.3892/mmr.2012.813 CrossRefPubMed

66.

Tsao KC, Wu TL, Chang PY, Sun CF, Wu LL, Wu JT (2007) Multiple risk markers for atherogenesis associated with chronic inflammation are detectable in patients with renal stones. J Clin Lab Anal 21(6):426–431. https://doi.org/10.1002/jcla.20215 CrossRefPubMedPubMedCentral

67.

Boonla C, Wunsuwan R, Tungsanga K, Tosukhowong P (2007) Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res 35(4):185–191. https://doi.org/10.1007/s00240-007-0098-0 CrossRefPubMed

68.

Ma MC, Chen YS, Huang HS (2014) Erythrocyte oxidative stress in patients with calcium oxalate stones correlates with stone size and renal tubular damage. Urology 83(2):510, e519–e517. https://doi.org/10.1016/j.urology.2013.09.050 CrossRef

69.

Fujii Y, Okada A, Yasui T, Niimi K, Hamamoto S, Hirose M, Kubota Y, Tozawa K, Hayashi Y, Kohri K (2013) Effect of adiponectin on kidney crystal formation in metabolic syndrome model mice via inhibition of inflammation and apoptosis. PLoS ONE 8(4):e61343. https://doi.org/10.1371/journal.pone.0061343 CrossRefPubMedPubMedCentral

70.

Hong SH, Lee HJ, Sohn EJ, Ko HS, Shim BS, Ahn KS, Kim SH (2013) Anti-nephrolithic potential of resveratrol via inhibition of ROS, MCP-1, hyaluronan and osteopontin in vitro and in vivo. Pharmacol Rep 65(4):970–979CrossRefPubMed

71.

Huang HS, Chen J, Chen CF, Ma MC (2006) Vitamin E attenuates crystal formation in rat kidneys: roles of renal tubular cell death and crystallization inhibitors. Kidney Int 70(4):699–710. https://doi.org/10.1038/sj.ki.5001651 CrossRefPubMed

72.

Lee HJ, Jeong SJ, Park MN, Linnes M, Han HJ, Kim JH, Lieske JC, Kim SH (2012) Gallotannin suppresses calcium oxalate crystal binding and oxalate-induced oxidative stress in renal epithelial cells. Biol Pharm Bull 35(4):539–544CrossRefPubMedPubMedCentral

73.

Davalos M, Konno S, Eshghi M, Choudhury M (2010) Oxidative renal cell injury induced by calcium oxalate crystal and renoprotection with antioxidants: a possible role of oxidative stress in nephrolithiasis. J Endourol 24(3):339–345. https://doi.org/10.1089/end.2009.0205 CrossRefPubMed

74.

Holoch PA, Tracy CR (2011) Antioxidants and self-reported history of kidney stones: the National Health and Nutrition Examination Survey. J Endourol 25(12):1903–1908. https://doi.org/10.1089/end.2011.0130 CrossRefPubMed

75.

DeLuca HF (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80(6 Suppl):1689s–1696sCrossRefPubMed

76.

Hossein-nezhad A, Holick MF (2013) Vitamin D for health: a global perspective. Mayo Clin Proc 88(7):720–755. https://doi.org/10.1016/j.mayocp.2013.05.011 CrossRefPubMed

77.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine S (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1930. https://doi.org/10.1210/jc.2011-0385 CrossRefPubMed

78.

Kennel KA, Drake MT, Hurley DL (2010) Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc 85(8):752–758. https://doi.org/10.4065/mcp.2010.0138 CrossRefPubMedPubMedCentral

79.

Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP (2014) Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 348:g2035. https://doi.org/10.1136/bmj.g2035 CrossRefPubMedPubMedCentral

80.

Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM, Alvarez JA, Boxer RS, Dalbeni A, Gepner AD, Isbel NM, Larsen T, Nagpal J, Petchey WG, Stricker H, Strobel F, Tangpricha V, Toxqui L, Vaquero MP, Wamberg L, Zittermann A, Witham MD (2015) Effect of Vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med 175(5):745–754. https://doi.org/10.1001/jamainternmed.2015.0237 CrossRefPubMedPubMedCentral

81.

Wu C, Qiu S, Zhu X, Li L (2017) Vitamin D supplementation and glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Metabolism 73:67–76. https://doi.org/10.1016/j.metabol.2017.05.006 CrossRefPubMed

82.

Rejnmark L, Bislev LS, Cashman KD, Eiriksdottir G, Gaksch M, Grubler M, Grimnes G, Gudnason V, Lips P, Pilz S, van Schoor NM, Kiely M, Jorde R (2017) Non-skeletal health effects of vitamin D supplementation: a systematic review on findings from meta-analyses summarizing trial data. PLoS ONE 12(7):e0180512. https://doi.org/10.1371/journal.pone.0180512 CrossRefPubMedPubMedCentral

83.

Wobke TK, Sorg BL, Steinhilber D (2014) Vitamin D in inflammatory diseases. Front Physiol 5:244. https://doi.org/10.3389/fphys.2014.00244 CrossRefPubMedPubMedCentral

84.

Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, Goleva E (2012) Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 188(5):2127–2135. https://doi.org/10.4049/jimmunol.1102412 CrossRefPubMed

85.

Jain SK, Micinski D (2013) Vitamin D upregulates glutamate cysteine ligase and glutathione reductase, and GSH formation, and decreases ROS and MCP-1 and IL-8 secretion in high-glucose exposed U937 monocytes. Biochem Biophys Res Commun 437(1):7–11. https://doi.org/10.1016/j.bbrc.2013.06.004 CrossRefPubMedPubMedCentral

86.

Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM (2012) Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 302(6):F647–F657. https://doi.org/10.1152/ajprenal.00090.2011 CrossRefPubMed

87.

Perez-Hernandez N, Aptilon-Duque G, Nostroza-Hernandez MC, Vargas-Alarcon G, Rodriguez-Perez JM, Blachman-Braun R (2016) Vitamin D and its effects on cardiovascular diseases: a comprehensive review. Korean J Intern Med 31(6):1018–1029. https://doi.org/10.3904/kjim.2015.224 CrossRefPubMedPubMedCentral

88.

Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC (2007) 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282(41):29821–29830. https://doi.org/10.1074/jbc.M705495200 CrossRefPubMed

89.

Weng S, Sprague JE, Oh J, Riek AE, Chin K, Garcia M, Bernal-Mizrachi C (2013) Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice. PLoS ONE 8(1):e54625. https://doi.org/10.1371/journal.pone.0054625 CrossRefPubMedPubMedCentral

90.

Kong J, Zhu X, Shi Y, Liu T, Chen Y, Bhan I, Zhao Q, Thadhani R, Li YC (2013) VDR attenuates acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system. Mol Endocrinol 27(12):2116–2125. https://doi.org/10.1210/me.2013-1146 CrossRefPubMedPubMedCentral

91.

Deng X, Cheng J, Shen M (2016) Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress. J Endocrinol Invest 39(6):657–666. https://doi.org/10.1007/s40618-015-0414-4 CrossRefPubMed

92.

Garcia IM, Altamirano L, Mazzei L, Fornes M, Cuello-Carrion FD, Ferder L, Manucha W (2014) Vitamin D receptor-modulated Hsp70/AT1 expression may protect the kidneys of SHRs at the structural and functional levels. Cell Stress Chaperones 19(4):479–491. https://doi.org/10.1007/s12192-013-0474-3 CrossRefPubMed

93.

Carrara D, Bernini M, Bacca A, Rugani I, Duranti E, Virdis A, Ghiadoni L, Taddei S, Bernini G (2014) Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D. J Renin Angiotensin Aldosterone Syst 15(1):82–87. https://doi.org/10.1177/1470320312471149 CrossRefPubMed

94.

Bernini G, Carrara D, Bacca A, Carli V, Virdis A, Rugani I, Duranti E, Ghiadoni L, Bernini M, Taddei S (2013) Effect of acute and chronic vitamin D administration on systemic renin angiotensin system in essential hypertensives and controls. J Endocrinol Invest 36(4):216–220. https://doi.org/10.1007/bf03347275 CrossRefPubMed

95.

Ozkan B, Hatun S, Bereket A (2012) Vitamin D intoxication. Turk J Pediatr 54(2):93–98PubMed

96.

Hu H, Zhang J, Lu Y, Zhang Z, Qin B, Gao H, Wang Y, Zhu J, Wang Q, Zhu Y, Xun Y, Wang S (2017) Association between circulating vitamin D level and urolithiasis: a systematic review and meta-analysis. Nutrients 9(3):E301. https://doi.org/10.3390/nu9030301 CrossRefPubMed

97.

Malihi Z, Wu Z, Stewart AW, Lawes CM, Scragg R (2016) Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr 104(4):1039–1051. https://doi.org/10.3945/ajcn.116.134981 CrossRefPubMed

98.

Leaf DE, Korets R, Taylor EN, Tang J, Asplin JR, Goldfarb DS, Gupta M, Curhan GC (2012) Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers. Clin J Am Soc Nephrol 7(5):829–834. https://doi.org/10.2215/CJN.11331111 CrossRefPubMed

99.

Ferroni MC, Rycyna KJ, Averch TD, Semins MJ (2017) Vitamin D repletion in kidney stone formers: a randomized controlled trial. J Urol 197(4):1079–1083. https://doi.org/10.1016/j.juro.2016.10.057 CrossRefPubMed

100.

Dion M, Ankawi G, Chew B, Paterson R, Sultan N, Hoddinott P, Razvi H (2016) CUA guideline on the evaluation and medical management of the kidney stone patient: 2016 update. Can Urol Assoc J 10(11–12):E347–E358. https://doi.org/10.5489/cuaj.4218 CrossRefPubMedPubMedCentral

101.

Pipili C, Oreopoulos DG (2012) Vitamin D status in patients with recurrent kidney stones. Nephron Clin Pract 122(3–4):134–138. https://doi.org/10.1159/000351377 CrossRefPubMed

102.

Girón-prieto MS, Del Carmen Cano-garcía M, Arrabal-polo M, Poyatos-andujar A, Quesada-charneco M, de Haro-Muñoz T, Arias-santiago S, Arrabal-martín M (2016) Analysis of vitamin D deficiency in calcium stone-forming patients. Int Urol Nephrol 48(8):1243–1246. https://doi.org/10.1007/s11255-016-1290-3 CrossRefPubMed

103.

Hashemipour S, Larijani B, Adibi H, Javadi E, Sedaghat M, Pajouhi M, Soltani A, Shafaei AR, Hamidi Z, Fard AR, Hossein-Nezhad A, Booya F (2004) Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health 4:38. https://doi.org/10.1186/1471-2458-4-38 CrossRefPubMedPubMedCentral

Title: Vitamin D and calcium kidney stones: a review and a proposal
Authors: Sanaz Tavasoli
Maryam Taheri
Publication date: 01-01-2019
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 1/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-018-1965-z

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Improved voiding function by deep brain stimulation in traumatic brain-injured animals with bladder dysfunctions

The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study

The creatinine/cystatin C ratio provides effective evaluation of muscle mass in kidney transplant recipients

Prevalence of pulmonary hypertension in peritoneal dialysis patients: a meta-analysis

The predictive value of malnutrition for functional and cognitive status in elderly hemodialysis patients

The association between autosomal dominant polycystic kidney disease and cancer

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage